NeOnc Technologies Holdings, Inc. (NTHI) has a MoatMap StockRank of 1/100 based on Quality (14/100), Value (33/100), and Momentum (17/100) factor scores. The current signal is STRONG SELL. Pre-revenue biotechnology firm with high cash burn and unproven clinical pipeline, unsuitable for a concentrated quality-first book.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for difficult-to-treat cancers, particularly brain tumors, using proprietary nanotechnology and drug delivery systems. The company's unique approach aims to overcome the blood-brain barrier, allowing for targeted drug delivery to enhance efficacy and reduce systemic toxicity. NeOnc seeks to address significant unmet medical needs in oncology.
| Price | $4.42 |
| Market Cap | $125M |
| P/E (Forward) | -6.06 |
| Price/Book | -8.33 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-2M |
NeOnc Technologies Holdings, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).